Ali Farman, Arshad Khurram, Szpunar Susan, Daher Edouard
Medicine, Ascension St. John Hospital and Medical Center, Detroit, USA.
Internal Medicine, Corewell Health East Dearborn, Dearborn, USA.
Cureus. 2024 May 8;16(5):e59910. doi: 10.7759/cureus.59910. eCollection 2024 May.
Background In the emergency department (ED), the diagnosis of non-ST-elevation myocardial infarction (NSTEMI) is primarily based on the presence or absence of elevated cardiac troponin levels, ECG changes, and clinical presentation. However, limited data exist regarding the incidence, clinical characteristics, and predictive value of different cardiac diagnostic tests and outcomes in patients with non-acute coronary syndrome (ACS)-related troponin elevation. Our study aimed to determine the percentage of patients with elevated troponin levels who had true ACS and identify various risk factors associated with true ACS in these patients. Methodology This was a single-center retrospective study. We performed a chart review of patients who presented to the ED from January 1, 2016, to December 31, 2017, and were admitted to the hospital with an elevated cardiac troponin I level in the first 12 hours after ED presentation with a diagnosis of NSTEMI. True ACS was defined as (a) patients with typical symptoms of ischemia and ECG ischemic changes and (b) patients with atypical symptoms of myocardial ischemia or without symptoms of ischemia and new segmental wall motion abnormalities on echocardiogram or evidence of culprit lesion on angiography. A logistic regression model was used to determine the association between risk factors and true ACS. Results A total of 204 patients were included in this study. The mean age of the study group was 67.4 ± 14.5 years; 53.4% (n = 109) were male, and 57.4% (n = 117) were Caucasian. In our study, 51% of patients were found to have true ACS, and the remaining 49% had a non-ACS-related elevation in troponins. Most patients without ACS had alternate explanations for elevated troponin levels. The presence of chest pain (odds ratio (OR) = 3.7, 95% confidence interval (CI) = 1.8-7.7, p = 0.001), tobacco smoking (OR = 4, 95% CI = 1.06-3.8, p = 0.032), and wall motion abnormalities on echocardiogram (OR = 3.8, 95% CI = 1.8-6.5, p = 001) were associated with increased risk of true ACS in patients with elevated troponins. Conclusions Cardiac troponin levels can be elevated in hospitalized patients with various medical conditions, in the absence of ACS. The diagnosis of ACS should not be solely based on elevated troponin levels, as it can lead to expensive workup and utilization of hospital resources.
背景 在急诊科(ED),非ST段抬高型心肌梗死(NSTEMI)的诊断主要基于心肌肌钙蛋白水平是否升高、心电图变化以及临床表现。然而,关于非急性冠状动脉综合征(ACS)相关肌钙蛋白升高患者中不同心脏诊断检查的发生率、临床特征、预测价值及预后的数据有限。我们的研究旨在确定肌钙蛋白水平升高且患有真正ACS的患者比例,并识别这些患者中与真正ACS相关的各种危险因素。
方法 这是一项单中心回顾性研究。我们对2016年1月1日至2017年12月31日期间就诊于急诊科且在急诊科就诊后12小时内心肌肌钙蛋白I水平升高并被诊断为NSTEMI而入院的患者进行了病历审查。真正的ACS定义为:(a)有典型缺血症状和心电图缺血性改变的患者;(b)有非典型心肌缺血症状或无缺血症状且超声心动图有新的节段性室壁运动异常或血管造影有罪犯病变证据的患者。使用逻辑回归模型确定危险因素与真正ACS之间的关联。
结果 本研究共纳入204例患者。研究组的平均年龄为67.4±14.5岁;53.4%(n = 109)为男性,57.4%(n = 117)为白种人。在我们的研究中,发现51%的患者患有真正的ACS,其余49%的患者肌钙蛋白升高与非ACS相关。大多数无ACS的患者肌钙蛋白水平升高有其他原因。胸痛的存在(比值比(OR)= 3.7,95%置信区间(CI)= 1.8 - 7.7,p = 0.001)、吸烟(OR = 4,95% CI = 1.06 - 3.8,p = 0.032)以及超声心动图上的室壁运动异常(OR = 3.8,95% CI = 1.8 - 6.5,p = 0.001)与肌钙蛋白升高患者发生真正ACS的风险增加相关。
结论 在无ACS的情况下,各种医疗状况的住院患者心肌肌钙蛋白水平可能会升高。ACS的诊断不应仅基于肌钙蛋白水平升高,因为这可能导致昂贵的检查和医院资源的利用。